Dan Ives, Wedbush Securities global head of technology research and senior equity analyst, joins 'Squawk Box' to discuss ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Equities researchers at Wedbush lowered their FY2025 earnings per share estimates for shares of CareTrust REIT in a research report issued on Tuesday, February 18th. Wedbush analyst R. Anderson now ...

If the Department of Defense goes through budget cuts as suggested by a leaked memo, Palantir Technologies (PLTR) would have ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

Wedbush downgraded Jack in the Box (JACK) to Neutral from Outperform with a price target of $40, down from $50. While Jack in the Box’s ...

Wedbush analyst Robert Driscoll last night initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their Outperform rating and $550 price target on the stock. While concerns ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for ...

Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...

Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...